Get the Stockscreener App
17.22
1.37%
-0.24
After Hours:
17.21
-0.010
-0.06%
Adaptive Biotechnologies Corp stock is traded at $17.22, with a volume of 6.86M.
It is down -1.37% in the last 24 hours and up +34.22% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
See More
Previous Close:
$17.46
Open:
$16.155
24h Volume:
6.86M
Relative Volume:
3.35
Market Cap:
$2.76B
Revenue:
$295.41M
Net Income/Loss:
$-49.64M
P/E Ratio:
-52.60
EPS:
-0.3274
Net Cash Flow:
$-29.54M
1W Performance:
-0.81%
1M Performance:
+34.22%
6M Performance:
+8.10%
1Y Performance:
+67.35%
1-Day Range:
$15.90
$18.06
1-Week Range:
$15.90
$19.52
52-Week Range:
$9.9551
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
17.22 | 2.79B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
472.63 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.35 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
573.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
128.34 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.54 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Stock Market Today: S&P 500 Futures Fall, Dow Gains Amid US-Iran Agreement, SPCX Stock Surge—Dave And Buster's, Western Digital In Focus - Benzinga
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares By Investing.com - Investing.com India
Executive at Adaptive Biotechnologies (ADPT) sells 5,000 shares under 10b5-1 plan - Stock Titan
[144] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
Adaptive Biotechnologies plans to separate MRD, Immune Medicine units - Investing.com
Adaptive Biotechnologies plans $250M convertible notes offering - Investing.com
Adaptive Biotechnologies stock falls on convertible debt plan By Investing.com - Investing.com India
Adaptive Biotechnologies proposes $250M convertible notes, plans MRD/Immune Medicine separation - TradingView
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering - The Manila Times
Adaptive Biotechnologies (NASDAQ: ADPT) to sell $250M converts and explore MRD–Immune Medicine split - Stock Titan
Adaptive Biotechnologies plans split: MRD tests vs AI immune unit - Stock Titan
Adaptive Biotechnologies lines up $250M note deal to repay debt, buy back shares - Stock Titan
Kennedy Capital Management LLC Trims Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors? - Yahoo Finance
Adaptive Biotechnologies Momentum Lifts Nasdaq Healthcare Focus - Kalkine Media
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap UpWhat's Next? - MarketBeat
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last? - Yahoo Finance
ADPT: Brokered notice to sell 5,000 shares (NASDAQ: ADPT) listed - Stock Titan
Adaptive Biotechnologies Corporation $ADPT Shares Sold by Amova Asset Management Americas Inc. - MarketBeat
Adaptive Biotechnologies (ADPT) shareholders back directors, pay and 2026 auditor - Stock Titan
Adaptive Biotechnologies CCO Bobulsky sells $198,000 in stock By Investing.com - Investing.com India
Adaptive Biotechnologies CCO Bobulsky sells $198,000 in stock - Investing.com UK
Adaptive Biotechnologies CPO Francis Lo sells $695k in stock - Investing.com UK
Adaptive Biotechnologies CPO Francis Lo sells $695k in stock By Investing.com - Investing.com India
Adaptive Biotechnologies (ADPT) CCO Bobulsky sells 11,000 shares under 10b5-1 plan - Stock Titan
ADPT (NASDAQ: ADPT) affiliate notifies planned sale after option exercise - Stock Titan
How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value Anchor - Yahoo Finance
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference - Yahoo Finance
Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026 - Insider Monkey
10 Best Growth Stocks Under $20 to Buy - Insider Monkey
Does ADPT’s clonoSEQ Spotlight at ASCO and EHA Reveal a Durable MRD Moat in Oncology? - simplywall.st
Jupiter Asset Management Ltd. Acquires 91,683 Shares of Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Hits Day High with 9.75% Surge in Stock Price - MarketsMojo
Adaptive Biotechnologies Announces Extensive Presence at ASCO and EHA Conferences Showcasing clonoSEQ Test for MRD Assessment - Quiver Quantitative
Blood cancer monitoring test featured in 33 studies at major oncology meetings - Stock Titan
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million - AOL.com
ADPT SEC FilingsAdaptive Biotechnologies 10-K, 10-Q, 8-K Forms - Stock Titan
Hear Adaptive Biotechnologies' June 3 investor talk live online - Stock Titan
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences - The Manila Times
Adaptive Biotechnologies CFO Kyle Piskel sells $40,619 in stock By Investing.com - Investing.com Canada
Adaptive Biotechnologies CFO Kyle Piskel sells $40,619 in stock - Investing.com
Adaptive Biotechnologies (ADPT) CFO tax-related share sale leaves 256,725 shares held - Stock Titan
UBS Group AG Purchases 257,947 Shares of Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Proposed sale of 3,160 RSUs by ADPT (NASDAQ: ADPT) reported - Stock Titan
Viking firms hold 18.8% of Adaptive Biotechnologies (NASDAQ: ADPT) - Stock Titan
ADPT Stock Price, Quote & Chart | ADAPTIVE BIOTECHNOLOGIES (NASDAQ:ADPT) - ChartMill
ADPT Maintained by Morgan Stanley -- Price Target Lowered to $18 - GuruFocus
Morgan Stanley Cuts Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $18.00 - MarketBeat
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong MRD Growth And Raised Full Year Guidance - Yahoo Finance
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):